Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients


Por: Lopez-Lerma, I, Penate, Y, Gallardo, F, Marti, RM, Mitxelena, J, Bielsa, I, Velasco-Tamariz, V, Yanguas-Bayona, JI, Sanchez-Sambucety, P, Garcia-Patos, V, Ortiz-Romero, PL, Pujol, RM and Estrach, T

Publicada: 1 nov 2018
Categoría: Dermatology

Resumen:
Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare primary cutaneous lymphoma of mature cytotoxic T cells. Initially, patients with SPTCL were treated with doxorubicin-based polychemotherapy. Objective: To analyze clinical, biologic, immunophenotypical, molecular, imaging, treatment, and outcome data reflecting the current state of knowledge. Methods: A retrospective multicenter study of 16 patients with SPTCL that was diagnosed between 1996 and 2016. Results: The female-to-male ratio was 1.7. The median age at diagnosis was 46.5 years. Patients presented with multiple nodular or plaque-like lesions preferentially affecting the legs and/or trunk. Histopathology typically showed a lobular panniculitis with individual adipocytes surrounded by atypical lymphocytes, usually with a CD3(+), CD4(-), CD8(+), CD56(-), TIA1 cytotoxic granule associated RNA binding protein 1-positive phenotype and high proliferation rate. SPTCL was associated with autoimmune diseases in 25% of patients, and with the development of hemophagocytic syndrome in 18% of patients. Oral steroids alone or in combination with low-dose methotrexate or cyclosporine A were the most common initial treatment, achieving a complete response in 85% of the treated patients. The median follow-up time was 14 months. The 5-year disease-specific survival rate was 85.7%. Limitations: This was a retrospective study. Conclusions: SPTCL has an excellent prognosis. Immunosuppressive agents can be considered for first-line treatment.

Filiaciones:
Lopez-Lerma, I:
 Hosp Univ Vall dHebron, Barcelona, Spain

Penate, Y:
 Complejo Hosp Univ Insular Maternoinfantil Gran C, Las Palmas Gran Canaria, Spain

Gallardo, F:
 Hosp Mar, Barcelona, Spain

Marti, RM:
 Hosp Arnau Vilanova, Lleida, Spain

Mitxelena, J:
 Complejo Hosp Navarra, Pamplona, Spain

:
 Hosp Univ Germans Trias i Pujol, Badalona, Spain

Velasco-Tamariz, V:
 Hosp Univ 12 Octubre, Madrid, Spain

Yanguas-Bayona, JI:
 Complejo Hosp Navarra, Pamplona, Spain

Sanchez-Sambucety, P:
 Complejo Asistencial Univ Leon, Leon, Spain

Garcia-Patos, V:
 Hosp Univ Vall dHebron, Barcelona, Spain

Ortiz-Romero, PL:
 Hosp Univ 12 Octubre, Madrid, Spain

Pujol, RM:
 Hosp Mar, Barcelona, Spain

Estrach, T:
 Hosp Clin, Leon, Spain
ISSN: 01909622





Journal of the American Academy of Dermatology
Editorial
Mosby Inc., 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 79 Número: 5
Páginas: 892-898
WOS Id: 000447147700020
ID de PubMed: 30126736

MÉTRICAS